Descemet’s Stripping Only… a substitute for DMEK? An update to a previous post

This is an update to a post published on 9/25/17. You can find the original post here.

Descemet’s Stripping Only…a substitute for DMEK?

 By Francis W. Price, Jr., MD & Matthew T. Feng, MD

We are always looking for better ways to correct the visual difficulties of patients with Fuchs’ dystrophy.  In fact, that is why we helped pioneer the evolution of corneal transplants from full-thickness grafts (penetrating keratoplasty) to PLK/DLEK to DSEK to DMEK.  Interest is building now to eliminate the transplant altogether and allow a person’s own endothelial cells to redistribute in a procedure called Descemet’s Stripping Only.

The corneal endothelium is a single layer of cells that lines the back surface of the cornea. These cells pump water out of the cornea to keep it crystal clear. In Fuchs’ dystrophy, these cells become unhealthy and die off, starting in the center and moving toward the periphery over time.  This allows fluid to build up in the cornea causing swelling and hazy vision. Eventually, blisters can develop; this can be painful and cause light sensitivity.

The corneal endothelial cells are attached to a thin membrane called Descemet’s membrane. In Fuchs’ dystrophy, abnormal deposits called “guttae” accumulate on Descemet’s membrane.  These guttae are like water drops on a windshield (guttae mean raindrops in Latin).  They distort the light coming into the cornea and also cause glare and halos and must be removed to improve vision.

A healthy endothelium compared to a diseased endothelium.

DMEK is a tried and true treatment for Fuchs’ dystrophy in which we remove the central corneal endothelium and Descemet’s membrane and implant healthy donor tissue, which has normal endothelial cells and a clear Descemet’s membrane without guttae.  It provides rapid and reliable visual recovery within 2 days to one month after surgery with minimal risk of immunologic graft rejection (<1% with appropriate use of eye drops).[reference] With DMEK, the risk of developing glaucoma is reduced because of the improved corticosteroid eye drop dosing regimens we have developed, and long term graft survival is excellent.

In contrast, we and others have tried Descemet’s Stripping Only (DSO) which is performed in the same manner as with DMEK, except a smaller area of the central area of Descemet’s Membrane is removed and no donor endothelium is transplanted.  We then wait to see if the surrounding endothelial cells migrate from the periphery to recover the central area.  There are two benefits of DSO that excited us. First, there would be no risk of immunologic graft rejection (0% rejection rate) since we are not using a donor cornea so there is no immune response to foreign tissue. Second, the need to use long term topical corticosteroids to prevent graft rejection would be eliminated thereby reducing the side effect of intraocular pressure elevation that can affect up to one-third of transplant recipients.

In a prior analysis of DSO, we removed a 6-mm diameter area of the diseased Descemet’s membrane but we found that recovery was incomplete—the endothelial cells never fully filled in the area of cells that we removed, even after waiting for months.

We, along with other surgeons, are now removing smaller areas of Descemet’s membrane (4 to 5 mm diameter area) and have a higher rate of clearing.  Despite these successes, DSO is not yet a replacement for DMEK for two primary reasons: clearing a smaller area may not always be sufficient to provide the best possible vision, and there is still the potential for prolonged corneal swelling that may last for months hindering visual recovery. By way of comparison, we typically remove unhealthy Descemet’s membrane and endothelium from a much larger area (over twice as big) when performing DSEK or DMEK. However, DSO may be a suitable first-line surgical treatment option prior to DMEK, for those willing to see if stripping alone will satisfactorily resolve their vision problems. If after a few months their cornea is not clear, they would then be a candidate for DMEK.

We have been told that patients are happy with the vision they get using a 4-mm area of treatment. But we wonder if they just notice some visual improvement with the central guttae removed without realizing how much better it could be if a wider area was treated. We know from laser refractive surgery (LASIK or PRK) that a small treatment zone causes patients to have significant glare and halos at night.  We also know that the intraocular lenses used in cataract surgery do not perform well when the clear optical zone is only a 4-mm diameter. Typically, clear zones of 6-mm diameter or more are needed to avoid glare and halos.

Many of our Fuchs’ dystrophy patients tell us they only need one eye treated because their other eye is doing fine.  But after DMEK, they realize the “good” eye was not as good as they thought, and then they want to have the second treated as soon as possible to eliminate glare and haze.  Similarly, in the wintertime when it snows, you can drive your car after just clearing a small area of the windshield, but obviously, it is much better to clear a larger area to view the periphery. Since guttae generally begin forming in the central portion of the cornea, DSO may be a better option for patients earlier in their Fuchs’ dystrophy onset rather than more advanced cases. Your surgeon will determine in you may be a candidate for DSO, or whether DMEK is more fitting. This is an example of when it’s best to seek evaluation as soon as you observe changes in your vision, as you may have more treatment options at that time.

The second concern with DSO is slow healing. Often with stripping alone, it takes several weeks to months for the cornea to clear.  In some cases it takes over 6 months.  There is evidence that when the cornea is continuously edematous (swollen) from non-functioning endothelium for 6 months or longer, permanent changes occur so that when the edema does resolve, the vision does not return to a level as good as it would have been if the cornea had cleared faster. Two centers found that if they waited over 6 months to replace a failed transplant, the visual results were disappointing.4,5  In contrast, we find that when we replace a failed transplant promptly, the visual results are excellent.6  The longer a cornea remains edematous, the more likely it is that vision will permanently deteriorate.

In summary, we look forward to continuing research to assure the cornea will reliably clear within a month or sooner with DSO and are actively conducting studies to optimize this treatment option for Fuchs’ dystrophy patients.  Two small studies found that the use of a “Rock Inhibitor” eye drop available outside the USA seemed to help the cornea clear faster and more reliably by helping the cells migrate and possibly regenerate.7 If you would like to learn more about DSO and determine if you are a candidate for a study, please call (317) 814-2996. Patients who have already had stripping alone and are dissatisfied with their vision or speed of recovery often remain candidates for DMEK and may benefit from evaluation sooner rather than later.    

Looking ahead, cell culture techniques are improving, and someday we may be able to harvest your blood cells and reprogram them to become corneal endothelial cells.  But until we can either do that or use medications to get your peripheral corneal endothelial cells to reliably heal the central cornea in less than a month, we will continue to recommend DMEK as the optimal treatment option for most patients with Fuchs’ dystrophy who are not able to face a potentially long recovery with DSO.

We certainly live in an exciting time with new developments occurring continually around the world. So stay tuned!

 

References:

  1. Bleyen et al. Spontaneous corneal clearing after Descemet’s stripping. Ophthalmology 2013l120:215.
  2. Arbelaez et al. Long-term follow-up and complications of stripping descemet membrane without placement of graft in eyes with Fuchs endothelial dystrophy. Cornea 2014 33:1295-1299 (our study)
  3. Koenig SB. Planned Descemetorhexis Without Endothelial Keratoplasty in Eyes With Fuchs Corneal Endothelial Dystrophy. Cornea 2015;34:1149-51.
  4. Baydoun et al. Repeat Descemet membrane endothelial keratoplasty after complicated primary Descemet membrane endothelial keratoplasty. Ophthalmology 2015; 122:8-16.
  5. Cirkovic et al. Clinical and ultrastructural characteristics of graft failure in DMEK: 1-year results after repeat DMEK. Cornea 2015; 34:11-7
  6. Price et al. Repeat Descemet Membrane Endothelial Keratoplasty: Secondary Grafts with Early Intervention Are Comparable with Fellow-Eye Primary Grafts. Ophthalmology 2015;122:1639-44.
  7. Moloney et al. Descemetorhexis Without Grafting for Fuchs Endothelial Dystrophy-Supplementation With Topical Ripasudil. Cornea 2017;36:642-648.

Leave a Reply

Fields marked with * are required.

Back to Top

Contact Us

Required fields

DO NOT USE THIS FORM IF YOU HAVE AN URGENT NEED TO BE SEEN. CALL OUR OFFICE.

By checking the box on the contact form, you agree to the Terms of Use listed here: Communications through our website or via email are not encrypted and are not necessarily secure. Use of the internet or email is for your convenience only, and by using them, you assume the risk of unauthorized use. By checking this box you hereby agree to hold Price Vision Group, its doctors and affiliates, harmless from any hacking or any other unauthorized use of your personal information by outside parties.

Indianapolis, IN
(800) 317-3937

Price Vision Group 9002 North Meridian Street #100
Indianapolis, IN 46260
Monday–Friday: 8 a.m.–5 p.m.
(317) 844-5530


Price Vision Group is a global leader in corneal transplant, cataract surgery, keratoconus treatment, PRK and LASIK. At our center in Indianapolis, we see patients from Indiana cities including Fishers, Carmel, Noblesville, Avon, and Greenwood, as well as people who travel from across the U.S. and even abroad for treatment by our renowned physicians.

Website Design & Marketing by Etna Interactive